Pharmacotherapy for HIV+ Stimulant Dependent Individuals
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The hypotheses of this study are:
1. Ondansetron will show a decrease in cocaine use from baseline in individuals with HIV
who are cocaine using.
2. Ondansetron will show a decrease in cravings from baseline in individuals with HIV who
are cocaine using.
After informed consent and screening, HIV infected individuals who are cocaine dependent and
qualify for the study will be offered ondansetron 4mg BID for six weeks in an open label
format 4mg BID has been found to have efficacy compared to placebo. At screening and then at
each visit, they will be asked to provide urine and a drug of abuse screen will be conducted
to assess for cocaine. They will be asked to detail their recent cocaine use in the last
month and then will be given a visual analog scale to assess their craving for cocaine. They
will be asked to return weekly for 6 weeks to receive a week's supply of ondansetron and to
give a urine sample that will test for cocaine. They will fill out a time line follow back
for the past week and asked to assess their craving for cocaine on a visual analog scale.